|
시장보고서
상품코드
2051128
말라리아 백신 시장 : 백신 유형별, 병원체별, 연령별, 유통 채널별, 최종사용자별, 지역별Malaria Vaccines Market, By Vaccine Type, By Agent, By Age, By Distribution Channel, By End Users, By Geography |
||||||
말라리아 백신 시장은 2026년에 7억 달러로 추정되며, 2033년까지 16억 3,660만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 12.9%로 성장할 것으로 전망됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 7억 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026년부터 2033년까지 예측 기간 CAGR: | 12.90% | 2033년 금액 예측: | 16억 3,660만 달러 |
말라리아는 감염된 열대열 모기에 물려 사람에게 전파되는 기생충에 의해 발생하는 생명을 위협하는 질병입니다. 살충제 처리망, 살충제 살포, 항말라리아 약품 등 현재 사용 가능한 말라리아 예방 및 대책 전략은 말라리아의 확산을 억제하기에 충분하지 않은 것으로 밝혀졌습니다. 따라서 말라리아 백신은 말라리아가 유행하는 지역에서 말라리아의 이환율과 사망률을 낮추기 위한 긴급하고 필수적인 공중보건 도구가 되고 있습니다. 백신은 대규모 의료 인프라 없이도 장기적인 면역력을 제공할 수 있기 때문에 말라리아 퇴치 목표를 달성하기 위한 비용 효율적이고 지속가능한 해결책이 될 수 있습니다.
시장 역학
세계 말라리아 백신 시장은 전 세계, 특히 아프리카 국가들의 높은 말라리아 질병 부담, 국제보건기구의 말라리아 백신 개발에 대한 막대한 자금 지원, 그리고 중요한 공중보건 대책으로서 백신의 수용성 확대에 의해 주도되고 있습니다. 그러나 말라리아 원충의 복잡한 수명주기와 방어 면역 반응에 대한 종합적인 이해 부족으로 인한 효과적인 말라리아 백신 개발의 기술적 어려움은 여전히 시장의 잠재력을 억제하고 있습니다. 한편, 백신학, 면역학, 병원체 유전체학 분야의 지속적인 발전은 새로운 백신 설계 접근법과 항원 표적 개발을 위한 기회를 창출하고 있습니다. 생산능력 확대와 더불어 세계보건기구(WHO), 보건 분야 적정기술 프로그램(PATH), 말라리아 백신 이니셔티브(PATH MVI) 및 각국의 예방접종 프로그램과의 협력을 통해 말라리아가 유행하는 지역 주민들에게 백신을 접종할 수 있는 기회를 제공할 수 있습니다. 백신이 공급될 때 접종이 이루어질 수 있도록 하는 것이 중요합니다.
본 조사의 주요 특징
이 보고서는 세계 말라리아 백신 시장에 대한 상세한 분석을 제공하며, 2025년을 기준 연도로 하여 예측 기간(2026-2033년)의 시장 규모와 연평균 성장률(CAGR)을 조사하여 제시합니다.
이 보고서는 각 부문의 잠재적 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
또한 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채택한 경쟁 전략에 대한 중요한 인사이트를 제공합니다.
이 조사는 다음과 같은 매개 변수를 기반으로 세계 말라리아 백신 시장의 주요 기업 프로파일을 작성했습니다. 구체적으로 기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적 및 전략 등입니다.
본 조사에서 다루고 있는 주요 기업으로는 GlaxoSmithKline plc, Sanaria Inc., Nobelpharma Co., Sumaya Biotech, GenVec, Merck & Co., Inc., Pfizer Inc., Johnson & Johnson, Bharat Biotech, Serum Institute of India, Takeda Pharmaceutical Company, Novavax, Inc., Inovio Pharmaceutical, Vaxart, Inc., BioNTech SE가 포함됩니다.
이 보고서는 각 기업의 마케팅 담당자와 경영진이 향후 제품 출시, 제품 개선, 시장 확대 및 마케팅 전략과 관련하여 정보에 입각한 의사결정을 내릴 수 있도록 돕습니다.
세계 말라리아 백신 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 다양한 이해관계자를 대상으로 합니다.
이해관계자들은 세계 말라리아 백신 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 말라리아 백신 시장 : 백신 유형별, 2021-2033년
제5장 세계의 말라리아 백신 시장 : 병원체별, 2021-2033년
제6장 세계의 말라리아 백신 시장 : 연령층별, 2021-2033년
제7장 세계의 말라리아 백신 시장 : 유통 채널별, 2021-2033년
제8장 세계의 말라리아 백신 시장 : 최종사용자별, 2021-2033년
제9장 세계의 말라리아 백신 시장 : 지역별, 2021-2033년
제10장 경쟁 구도
제11장 애널리스트의 제안
제12장 참고문헌 및 조사 방법
KSM 26.06.16Malaria Vaccines Market is estimated to be valued at USD 700.0 Mn in 2026 and is expected to reach USD 1,636.6 Mn by 2033, growing at a compound annual growth rate (CAGR) of 12.9% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 700 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 12.90% | 2033 Value Projection: | USD 1,636.6 Mn |
Malaria is a life-threatening disease caused by parasites that are transmitted to people through the bites of infected Anopheles mosquitoes. The currently available strategies for malaria prevention and control such as insecticide treated nets, spraying of insecticides and antimalarial drugs are proving insufficient to curb the spread of the disease. This makes malaria vaccines an urgent and vital public health tool to reduce malaria morbidity and mortality in endemic regions. Vaccines can provide long lasting immunity without requiring large healthcare infrastructure, thereby offering a cost-effective and sustainable solution towards malaria elimination goals.
Market Dynamics
The global malaria vaccines market is primarily driven by the high disease burden of malaria worldwide, especially in African countries, massive funding for malaria vaccine development from global health organizations and growing acceptance of vaccines as an important public health intervention. However, technical challenges in developing an effective malaria vaccine owing to the complex life cycle of parasite Plasmodium and lack of comprehensive understanding of protective immune responses continue to restrain market potential. Meanwhile, ongoing advancements in vaccinology, immunology, and pathogen genomics have created opportunities for the development of novel vaccine design approaches and antigen targets. Further opportunities lie in expanding manufacturing capacity and ensuring successful uptake of malaria vaccines, once available, in malaria endemic populations through coordinated efforts of World Health Organization (WHO), Program for Appropriate Technology in Health, Malaria Vaccine Initiative (PATH MVI), and government immunization programs.
Key Features of the Study
This report provides in-depth analysis of the global malaria vaccines market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global malaria vaccines market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include GlaxoSmithKline plc, Sanaria Inc., Nobelpharma Co., Sumaya Biotech, GenVec, Merck & Co., Inc., Pfizer Inc., Johnson & Johnson, Bharat Biotech, Serum Institute of India, Takeda Pharmaceutical Company, Novavax, Inc., Inovio Pharmaceuticals, Vaxart, Inc., and BioNTech SE.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global malaria vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global malaria vaccines market.
Market Segmentation
- Vaccine Type Insights (Revenue, USD Mn, 2021 - 2033)
- Pre-Erythrocytic Vaccines
- Erythrocytic Vaccines
- Multi-Antigen Vaccines
- Agent Insights (Revenue, USD Mn, 2021 - 2033)
- Plasmodium Falciparum
- Plasmodium Vivax
- Anopheles Species
- Age Insights (Revenue, USD Mn, 2021 - 2033)
- Pediatric
- Adult
- Distribution Channel Insights (Revenue, USD Mn, 2021 - 2033)
- Public
- Private
- End Users Insights (Revenue, USD Mn, 2021 - 2033)
- Hospitals
- Specialty Clinics
- Community Health Centers
- Homecare
- Regional Insights (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- GlaxoSmithKline plc
- Sanaria Inc.
- Nobelpharma Co.
- Sumaya Biotech
- GenVec
- Merck & Co., Inc.
- Pfizer Inc.
- Johnson & Johnson
- Bharat Biotech
- Serum Institute of India
- Takeda Pharmaceutical Company
- Novavax, Inc.
- Inovio Pharmaceuticals
- Vaxart, Inc.
- BioNTech SE
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Malaria Vaccines Market, By Vaccine Type
- Global Malaria Vaccines Market, By Agent
- Global Malaria Vaccines Market, By Age
- Global Malaria Vaccines Market, By Distribution Channel
- Global Malaria Vaccines Market, By End Users
- Global Malaria Vaccines Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Malaria Vaccines Market, By Vaccine Type, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Pre-Erythrocytic Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Erythrocytic Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Multi-Antigen Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
5. Global Malaria Vaccines Market, By Agent, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Plasmodium Falciparum
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Plasmodium Vivax
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Anopheles Species
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
6. Global Malaria Vaccines Market, By Age, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
7. Global Malaria Vaccines Market, By Distribution Channel, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Public
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Private
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
8. Global Malaria Vaccines Market, By End Users, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Community Health Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Homecare
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
9. Global Malaria Vaccines Market, By Region, 2021 - 2033, Value (USD Mn)
- Introduction
- Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Mn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2033, Value (USD Mn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Vaccine Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Agent, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Age, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End Users, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Vaccine Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Agent, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Age, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End Users, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Vaccine Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Agent, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Age, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End Users, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Vaccine Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Agent, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Age, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End Users, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Vaccine Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Agent, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Age, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End Users, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Vaccine Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Agent, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Age, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End Users, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Mn)
- South Africa
- North Africa
- Central Africa
10. Competitive Landscape
- GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanaria Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Nobelpharma Co.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sumaya Biotech
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GenVec
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bharat Biotech
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Serum Institute of India
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Takeda Pharmaceutical Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novavax, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Inovio Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Vaxart, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- BioNTech SE
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
11. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
12. References and Research Methodology
- References
- Research Methodology
- About us
